Obesity is a chronic disease, not a failure of willpower, according to medical experts and global health organizations. This perspective is gaining traction as pharmaceutical companies push for broader insurance coverage of recent weight-loss medications. The debate centers on whether public health systems should treat obesity with the same urgency and financial support as other chronic conditions like diabetes or hypertension.
The call for change comes amid rising global obesity rates, which have nearly tripled since 1975, according to the World Health Organization. In South Korea, where the discussion has recently intensified, over one-third of adults are now classified as overweight or obese. Advocates argue that recognizing obesity as a medical condition requiring treatment — rather than blaming individuals for lack of effort — could improve health outcomes and reduce long-term healthcare costs.
At the heart of the conversation is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist marketed under the brand name Mounjaro. Originally approved for type 2 diabetes, the drug has shown significant weight loss effects in clinical trials, leading to its investigation and approval for chronic weight management in several countries.
In a recent interview, a vice president at Eli Lilly, the pharmaceutical company that manufactures Mounjaro, emphasized that obesity should be treated as a disease requiring medical intervention, not merely a lifestyle issue. The executive argued that South Korea’s National Health Insurance Service should consider covering anti-obesity medications like tirzepatide for eligible patients, similar to how it covers treatments for other chronic illnesses.
This proposal has sparked debate among policymakers, healthcare providers, and patient advocates. Supporters point to evidence that sustained weight loss reduces the risk of comorbidities such as heart disease, stroke, and certain cancers. They also note that behavioral interventions alone often fail to produce lasting results for many individuals due to biological factors influencing appetite and metabolism.
Critics, however, raise concerns about the long-term safety, cost-effectiveness, and potential overreliance on pharmaceutical solutions. Some worry that widespread use of expensive weight-loss drugs could strain public health budgets without addressing root causes like food environments, socioeconomic disparities, and sedentary lifestyles.
Understanding Obesity as a Chronic Disease
The American Medical Association officially recognized obesity as a disease in 2013, a stance later echoed by the World Health Organization and numerous medical societies. This classification reflects growing scientific understanding of obesity as a complex condition influenced by genetic, hormonal, environmental, and behavioral factors.
Unlike simple weight gain, chronic obesity involves dysregulation of appetite control, energy expenditure, and fat storage mechanisms. Hormones like leptin and ghrelin, which signal hunger and fullness to the brain, often function abnormally in individuals with obesity. The body may defend a higher weight set point, making sustained weight loss tough through diet and exercise alone.
These biological realities assist explain why many people regain weight after initial loss, despite continued efforts. Medical professionals increasingly view obesity management as requiring long-term strategies — similar to hypertension or asthma — where medication may be one component of a comprehensive treatment plan.
In South Korea, the National Health Insurance Service currently covers certain obesity-related treatments, including bariatric surgery for patients with severe obesity and comorbidities. However, pharmacotherapy for weight management is not routinely reimbursed, leaving many patients to pay out-of-pocket for medications that can cost hundreds of dollars per month.
How Tirzepatide Works and What the Evidence Shows
Tirzepatide mimics the action of two gut hormones involved in regulating blood sugar and appetite: GIP and GLP-1. By activating these receptors, the drug enhances insulin secretion, slows gastric emptying, and reduces food intake, leading to improved glycemic control and weight loss.
In the SURMOUNT-1 trial, published in The New England Journal of Medicine, participants without diabetes who took tirzepatide lost an average of 15% to 21% of their body weight over 72 weeks, depending on the dose. This compared to just 2.4% in the placebo group. Over half of those on the highest dose lost at least 20% of their starting weight.
These results surpass those seen with earlier weight-loss medications and approach the efficacy typically associated with bariatric surgery. The drug received approval for chronic weight management in the United Kingdom in late 2023 and is under review by regulatory agencies in several other countries, including South Korea’s Ministry of Food and Drug Safety.
Common side effects include nausea, diarrhea, vomiting, and constipation — typically mild to moderate and often diminishing over time. Serious adverse events are rare but may include pancreatitis or gallbladder disease, requiring patient monitoring.
Stakeholder Perspectives and Policy Implications
Healthcare professionals specializing in endocrinology and metabolism generally support expanded access to obesity pharmacotherapy, particularly for patients with obesity-related complications. Dr. Sue Pedersen, an obesity medicine specialist in Canada, noted in a recent commentary that denying effective treatment based on stigma undermines principles of equitable care.
Patient advocacy groups have also voiced support. The World Obesity Federation emphasizes that access to evidence-based care should not depend on a person’s ability to pay. In a 2022 position statement, the organization called for obesity to be integrated into primary care systems with covered treatments, lifestyle support, and psychological care.
health economists caution about budget impact. A study published in The Lancet Public Health estimated that widespread use of GLP-1-based therapies could significantly increase national pharmaceutical expenditures, though long-term savings from reduced comorbidity treatment might offset some costs over time.
South Korea’s National Health Insurance Service evaluates new medications based on clinical effectiveness, safety, and cost-effectiveness through its Health Technology Assessment process. Any decision to cover tirzepatide for obesity would require submission of clinical and economic data, followed by review by expert committees.
What This Means for Patients and Public Health
For individuals living with obesity, the possibility of insurance-covered treatment could reduce financial barriers and improve access to care. However, experts stress that medication should complement — not replace — healthy eating, physical activity, and behavioral support. Comprehensive programs that include counseling, nutrition guidance, and ongoing monitoring tend to yield the best outcomes.
Public health officials also emphasize the importance of prevention. Even as treatment is essential for those already affected, addressing upstream factors such as food marketing, urban design, and socioeconomic inequities remains critical to reducing obesity prevalence at the population level.
As of now, tirzepatide is approved in South Korea for the treatment of type 2 diabetes but not yet for weight management. Patients seeking the drug for obesity must currently pay privately, with monthly costs estimated at over ₩500,000 (approximately $370 USD) depending on dosage and pharmacy.
The Ministry of Food and Drug Safety has not announced a timeline for reviewing tirzepatide’s obesity indication, but industry observers expect an application to be submitted in the coming months, following trends seen in other Asian markets.
The conversation around obesity as a treatable disease continues to evolve. Whether South Korea’s public health system will move to cover medications like Mounjaro remains uncertain — but the debate reflects a broader shift toward recognizing obesity not as a personal failing, but as a complex medical condition deserving of compassionate, evidence-based care.
For updates on regulatory decisions regarding weight-loss medications in South Korea, readers can consult the Ministry of Food and Drug Safety website or follow announcements from the National Health Insurance Service.
We welcome your thoughts on this important health issue. Share your perspective in the comments below, and consider sharing this article to help inform others about the evolving understanding of obesity and its treatment.